Savient Pharmaceuticals filed for bankruptcy protection and court approval to sell assets to a US WorldMeds unit.
Healthcare Health/Fitness
SAGE Therapeutics closes USD 20 million Series B funding round with USD 20 million
Biopharmaceutical firm SAGE Therapeutics scored USD 20 million from ARCH Venture Partners and Third Rock Ventures in its Series B funding round.
Zydus signs marketing agreement with Pieris AG
The therapeutic protein molecule Anticalin would be the subject of the an agreement between Zydus and Pieris.
Albion Ventures acquires Cisiv Ltd
Albion Ventures, the largest venture capitalist in the UK completed the investment in Cisiv Ltd. Albion Ventures recently completed the acquisition of Cisiv Ltd.
immatics biotechnologies closes Series D funding round
immatics raises EUR34 million in its latest Series D round financing. Clinical stage biopharmaceutical firm immatics biotechnologies GmbH had developed advanced a multi-peptide vaccine program providing active medication against cancer.
Latest News
Baird Capital's portfolio firm MedPlast had bought Orthoplastics together with co-investors JZ Capital Partners and River Cities Capital Funds.
Because of price caps and channel disruptions, the Indian drug market still is continuing its negative growth pattern.
Minnesota-based St. Jude Medical purchased California-based Nanostim Inc for a price tag of USD 123.5 million.
Molecular diagnostic test developer CardioDx Inc, who pioneered the heart disease test product Corus CAD, was set to raise almost USD86 million via a planned initial public offering.
B. Braun got regulatory clearance to increase its stake in German hospital operator Rhoen-Klinikum after filing a request last month, said a report from Reuters.
Vivus Inc. had signed a deal with Auxilium Pharmacauticals Inc to market its Stendra drug in the US market, said a Reuters report.
The price of USD315 million is what KIK Customs paid for Chemtura Corp's consumer product business.
In its second largest acquisition in the past six months, KKR had acquired 30% of India's Gland Pharma for USD150 million.
Otsuka Pharmaceutical announced today the completed acquisition of Astex Pharmaceuticals in a deal valued around USD900 million.
